|
|
Vaccine Detail
|
FVAX |
| Vaccine Information |
- Vaccine Name: FVAX
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007605
- Type: monoclonal antibodies
- Status: Licensed
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: TIM-4 blockade resulted in a marked increase in CD8+ T cells infiltrating the tumors, while the TIM-3 blockade had no significant effect on CD8+ T cells. NK1.1+ CD3− cells was much higher in mice treated with anti-TIM-3 mAb and FVAX compared to those treated with FVAX alone, whereas the treatment with anti-TIM-4 mAb and FVAX did not significantly alter the frequency of NK cells. Importantly, a combined blockade of TIM-3 and TIM-4 resulted in increased frequencies of both NK cells and CD8+ T cells in tumors(Baghdadi et al., 2013)
|
| References |
Baghdadi et al., 2013: Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer immunology, immunotherapy : CII. 2013; 62(4); 629-637. [PubMed: 23143694].
|
|
